Replies to post #1003 on Rexahn Pharmaceuticals, Inc. (REXN)

[surf1944]

Rexahn Pharmaceuticals Issued US Patent for Quinoxalinyl-piperazine Compounds
Business WirePress Release: Rexahn Pharmaceuticals, Inc. – 32 minutes ago

ROCKVILLE, Md.--(BUSINESS WIRE)--

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class oncology therapeutics, today announced that it has been issued a United States patent (No. 8,314,100), titled “1-[6,7-substituted alkoxyquinoxalinyl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives.”

This new patent covers Rexahn’s quinoxalinyl-piperazine compounds, the process for the preparation of such compounds and their pharmaceutical composition. The patent includes Rexahn’s RX-5902, a first-in-class p68 helicase inhibitor, that is an orally available new chemical entity exhibiting potent antitumor properties in several types of tumors. RX-5902 has also shown to possess strong anti-proliferative activity against known anti-cancer drug-resistant cancer cells, and a synergistic effect with known anti-cancer drugs.

Rexahn has previously been awarded patents for quinoxalinyl-piperazine compounds in Europe, Australia, Canada and Mexico.

“We are very pleased to gain this important intellectual property protection for this exciting class of compounds in oncology. This patent is significant step forward in the development of RX-5902, and further strengthens our overall global intellectual property position in oncology,” said Rick Soni, President of Rexahn.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.